Recent Updates
Recently added Catalysts

Coagulation Factor IX variant

Phase 2

Hemophilia B | Monoclonal antibody | Hematology |Gyre Therapeutics, Inc.|Last Updated: Aug 8, 2021

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical trial landscape

Coagulation Factor IX variant · 1 trial · 1 indication

Phase 2 1
NCT03995784Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia BHemophilia B
COMPLETED6 Analytics
PHASE2COMPLETED
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
Hemophilia BUnlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
Coagulation Factor IX variantBIOLOGICALSingle intravenous injection of CB2679d/Dalcinonacog alfa
Unlock Study Design Details